ABUS
Arbutus Biopharma Corp
NASDAQ: ABUS · HEALTHCARE · BIOTECHNOLOGY
$4.13
-0.48% today
Updated 2026-04-29
Market cap
$813.36M
P/E ratio
—
P/S ratio
57.75x
EPS (TTM)
$-0.17
Dividend yield
—
52W range
$3 – $5
Volume
2.5M
Arbutus Biopharma Corp (ABUS) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
5 of 8
Last 8 quarters
Avg EPS surprise
-18.1%
Last 4 quarters
Revenue YoY growth
-33.2%
Most recent quarter
EPS YoY growth
+86.3%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-2.7%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
-6.6%
2025-11-13
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-26 | $-0.01 | +54.3% | $4.60 | $4.66 | +1.3% |
| 2025-11-13 | $-0.04 | -33.3% | $4.84 | $4.52 | -6.6% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $-0.03 | $-0.01 | +54.3% | $1.05M | -33.2% |
| 2025-09-30 | $-0.03 | $-0.04 | -33.3% | $529000.00 | -60.5% |
| 2025-06-30 | $-0.04 | $0.01 | +125.0% | $10.74M | +522.2% |
| 2025-03-31 | $-0.15 | $-0.18 | -18.1% | $1.76M | +15.1% |
| 2024-12-31 | $-0.12 | $-0.10 | +14.5% | $1.57M | -26.6% |
| 2024-09-30 | $-0.09 | $-0.09 | +0.0% | $1.34M | -71.3% |
| 2024-06-30 | $-0.10 | $-0.11 | -10.0% | $1.73M | -62.9% |
| 2024-03-31 | $-0.11 | $-0.10 | +9.1% | $1.53M | -77.1% |
| 2023-12-31 | $-0.12 | $-0.12 | +0.0% | $2.15M | — |
| 2023-09-30 | $-0.11 | $-0.12 | -9.1% | $4.66M | — |
| 2023-06-30 | $-0.11 | $-0.10 | +9.1% | $4.65M | — |
| 2023-03-31 | $-0.14 | $-0.10 | +28.6% | $6.69M | — |
| 2022-12-31 | $-0.13 | $-0.14 | -7.7% | — | — |
Frequently asked questions
Has Arbutus Biopharma Corp beaten earnings estimates?
Arbutus Biopharma Corp has beaten Wall Street EPS estimates in 5 of its last 8 quarterly reports, with an average EPS surprise of -18.1% over the last 1 quarters.
How does ABUS stock react to earnings?
ABUS stock has moved an average of -2.7% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Arbutus Biopharma Corp's revenue growth rate?
Arbutus Biopharma Corp reported year-over-year revenue growth of -33.2% in its most recent quarter, with EPS growing +86.3% year-over-year.